GALECTIN THERAPEUTICS INC. - COMMON STOCK

Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

06 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022

08 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update

15 Aug 2022 07:00:02 By Nasdaq GlobeNewswire

Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024

26 Jul 2022 07:00:02 By Nasdaq GlobeNewswire

Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022

21 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress

23 May 2022 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update

16 May 2022 07:00:02 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

14 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update

31 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference

06 Jan 2022 07:00:03 By Nasdaq GlobeNewswire

Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein

21 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting

13 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

UPDATE – Galectin Therapeutics to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD

05 Nov 2021 15:24:47 By Nasdaq GlobeNewswire

Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD

27 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

UPDATE: Galectin Therapeutics to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021

05 Oct 2021 14:39:51 By Nasdaq GlobeNewswire

Galectin Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

05 Oct 2021 12:55:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Announces $20 Million Convertible Debt Financing from Its Chairman, Richard E. Uihlein

21 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics, Inc. to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

09 Sep 2021 08:00:02 By Nasdaq GlobeNewswire

Galectin Therapeutics Strengthens Leadership Team with Strategic Hires to Advance Programs in Cancer Immunotherapy and NASH Cirrhosis

30 Aug 2021 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2021, and Provides Business Update

16 Aug 2021 08:00:01 By Nasdaq GlobeNewswire